<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00615108</url>
  </required_header>
  <id_info>
    <org_study_id>502.519</org_study_id>
    <nct_id>NCT00615108</nct_id>
  </id_info>
  <brief_title>Nice Morning- Safety and Efficacy Observational Study of Telmisartan in Hypertensive Patients in Multicenters</brief_title>
  <official_title>Safety and Effectiveness of Micardis Tablets Taken Once Daily at 40 mg/Day and 80 mg/Day in Hypertension Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The purpose of this observational study is to survey the safety and effectiveness of the
      product under the real condition of usual practice in Taiwanese hypertensive patients. During
      the 8-week observation, the safety profiles and the clinical evaluation in between doses
      through blood pressure (BP) measurement for overall effectiveness of telmisartan therapy will
      be concluded.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients Achieving Blood Pressure (BP) Control</measure>
    <time_frame>01-Dec-2006 to 31-Dec-2008</time_frame>
    <description>BP control was defined as diastolic blood pressure/systolic blood pressure DBP/SBP&lt; 90/140 mm-Hg during observation period. BP is measured every four weeks. The observation period is 8 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving BP Response</measure>
    <time_frame>01-Dec-2006 to 31-Dec-2008</time_frame>
    <description>Achieving BP response was defined as reduction from baseline in sitting SBP or DBP &gt; 10 mmHg during the observational period. The observation period is 8 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Assessment by Patients</measure>
    <time_frame>01-Dec-2006 to 31-Dec-2008</time_frame>
    <description>Overall assessment was reported as a 5-point scale rated from 0 to 4 as below:
4: Outstanding 3: Very satisfactory 2: Satisfactory
1: Marginal 0: Not satisfactory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Assessment by Attending Physicians</measure>
    <time_frame>01-Dec-2006 to 31-Dec-2008</time_frame>
    <description>Overall assessment was reported as a 5-point scale rated from 0 to 4 as below:
4: Outstanding 3: Very satisfactory 2: Satisfactory
1: Marginal 0: Not satisfactory</description>
  </secondary_outcome>
  <enrollment type="Actual">3148</enrollment>
  <condition>Hypertension</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Hypertension patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Male or female. 2. Aged 20 to 80 years old. 3. Patients meet one of following two
        criteria:

          1. Adult essential hypertensive either newly diagnosed and untreated, or previously
             treated and uncontrolled patients; sitting blood pressure: systolic blood pressure
             (BP) &gt; 140 mmHg but &lt; 180 mmHg, and/or diastolic BP &gt; 90 mmHg but &lt; 110 mmHg).

          2. Patients who are assessed to benefit from the intake of angiotensin II receptor
             blocker (ARB) monotherapy or as add-on medication.

        Exclusion Criteria:

          1. Patients with contraindications to telmisartan use (as per the Micardis® Tablets
             package insert).

          2. Known hypersensitivity to the active ingredient or to any of the excipients of
             Micardis® Tablets.

          3. Any other clinical condition which, in the opinion of the attending physician, would
             not allow safe administration of the study medications.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigator Site</name>
      <address>
        <city>Changhua</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigator Site 1</name>
      <address>
        <city>Chiayi</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigator Site 2</name>
      <address>
        <city>Chiayi</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigator Site</name>
      <address>
        <city>Keelung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigator Site</name>
      <address>
        <city>Ksohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigator Site</name>
      <address>
        <city>Miaoli</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigator Site 1</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigator Site 2</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigator Site 1</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigator Site 2</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigator Site 1</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigator Site 2</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigator Site 3</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigator Site 4</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigator Site 5</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigator Site 6</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigator Site 7</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2008</study_first_submitted>
  <study_first_submitted_qc>February 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2008</study_first_posted>
  <results_first_submitted>December 16, 2009</results_first_submitted>
  <results_first_submitted_qc>December 16, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 26, 2010</results_first_posted>
  <last_update_submitted>February 28, 2014</last_update_submitted>
  <last_update_submitted_qc>February 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Hypertension Patients</title>
          <description>Telmisartan 40mg or 80 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3148"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2641"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="507"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="122"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="370"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hypertension Patients</title>
          <description>Telmisartan 40mg or 80 mg</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3148"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.04" spread="12.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1525"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1623"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients Achieving Blood Pressure (BP) Control</title>
        <description>BP control was defined as diastolic blood pressure/systolic blood pressure DBP/SBP&lt; 90/140 mm-Hg during observation period. BP is measured every four weeks. The observation period is 8 weeks.</description>
        <time_frame>01-Dec-2006 to 31-Dec-2008</time_frame>
        <population>Subjects include those who took 20mg, 40mg, 80mg and unknown dosage</population>
        <group_list>
          <group group_id="O1">
            <title>Micardis 40mg</title>
            <description>Telmisartan 40 mg</description>
          </group>
          <group group_id="O2">
            <title>Micardis 80mg</title>
            <description>Telmisartan 80 mg</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>Telmisartan 40mg or 80 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving Blood Pressure (BP) Control</title>
          <description>BP control was defined as diastolic blood pressure/systolic blood pressure DBP/SBP&lt; 90/140 mm-Hg during observation period. BP is measured every four weeks. The observation period is 8 weeks.</description>
          <population>Subjects include those who took 20mg, 40mg, 80mg and unknown dosage</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2406"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="2641"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving BP Response</title>
        <description>Achieving BP response was defined as reduction from baseline in sitting SBP or DBP &gt; 10 mmHg during the observational period. The observation period is 8 weeks.</description>
        <time_frame>01-Dec-2006 to 31-Dec-2008</time_frame>
        <population>Included the patients who took 20mg, 40mg, 80mg and unknown dosage.</population>
        <group_list>
          <group group_id="O1">
            <title>Micardis 40mg</title>
            <description>Telmisartan 40 mg</description>
          </group>
          <group group_id="O2">
            <title>Micardis 80mg</title>
            <description>Telmisartan 80 mg</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>Telmisartan 40mg or 80 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving BP Response</title>
          <description>Achieving BP response was defined as reduction from baseline in sitting SBP or DBP &gt; 10 mmHg during the observational period. The observation period is 8 weeks.</description>
          <population>Included the patients who took 20mg, 40mg, 80mg and unknown dosage.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2406"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="2641"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Achieving SBP &gt; 10 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="63"/>
                    <measurement group_id="O3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Achieving DBP &gt; 10 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Assessment by Patients</title>
        <description>Overall assessment was reported as a 5-point scale rated from 0 to 4 as below:
4: Outstanding 3: Very satisfactory 2: Satisfactory
1: Marginal 0: Not satisfactory</description>
        <time_frame>01-Dec-2006 to 31-Dec-2008</time_frame>
        <population>Included the patients who took 20mg, 40mg, 80mg and unknown dosage.</population>
        <group_list>
          <group group_id="O1">
            <title>Micardis 40mg</title>
            <description>Telmisartan 40 mg</description>
          </group>
          <group group_id="O2">
            <title>Micardis 80mg</title>
            <description>Telmisartan 80 mg</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>Telmisartan 40mg or 80 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Assessment by Patients</title>
          <description>Overall assessment was reported as a 5-point scale rated from 0 to 4 as below:
4: Outstanding 3: Very satisfactory 2: Satisfactory
1: Marginal 0: Not satisfactory</description>
          <population>Included the patients who took 20mg, 40mg, 80mg and unknown dosage.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2512"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="2791"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Outstanding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very satisfactory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfatory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Marginal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not satisfactory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Assessment by Attending Physicians</title>
        <description>Overall assessment was reported as a 5-point scale rated from 0 to 4 as below:
4: Outstanding 3: Very satisfactory 2: Satisfactory
1: Marginal 0: Not satisfactory</description>
        <time_frame>01-Dec-2006 to 31-Dec-2008</time_frame>
        <population>Included the patients who took 20mg, 40mg, 80mg and unknown dosage</population>
        <group_list>
          <group group_id="O1">
            <title>Micardis 40mg</title>
            <description>Telmisartan 40 mg</description>
          </group>
          <group group_id="O2">
            <title>Micardis 80mg</title>
            <description>Telmisartan 80 mg</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>Telmisartan 40mg or 80 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Assessment by Attending Physicians</title>
          <description>Overall assessment was reported as a 5-point scale rated from 0 to 4 as below:
4: Outstanding 3: Very satisfactory 2: Satisfactory
1: Marginal 0: Not satisfactory</description>
          <population>Included the patients who took 20mg, 40mg, 80mg and unknown dosage</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2512"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="2791"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Outstanding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very satisfactory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfactory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Marginal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not satisfactory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 Weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Hypertension Patients</title>
          <description>Telmisartan 40mg or 80 mg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="3148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypovolemic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3148"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3148"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3148"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3148"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3148"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3148"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3148"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3148"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3148"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3148"/>
              </event>
              <event>
                <sub_title>Ileal ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3148"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3148"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3148"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3148"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness, Dizzling</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Ischaemic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3148"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3148"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3148"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3148"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3148"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

